The KCNMB2 antibody targets the KCNMB2 protein, a member of the potassium channel subunit family that regulates the activity of calcium-activated potassium (KCa) channels, particularly the large-conductance BK (Big Potassium) channels. KCNMB2. encoded by the KCNMB2 gene, functions as a regulatory β-subunit modulating BK channel sensitivity to calcium and voltage, thereby influencing cellular excitability, smooth muscle relaxation, and neurotransmitter release. It is expressed in tissues such as the brain, vascular smooth muscle, and endocrine cells. Antibodies against KCNMB2 are critical tools for studying its expression, localization, and functional roles in physiological and pathological processes. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate conditions linked to BK channel dysregulation, including hypertension, neurological disorders, and cancer. Commercially available KCNMB2 antibodies are typically produced in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. Validation often involves knockout controls or siRNA-mediated silencing to confirm specificity. Research utilizing these antibodies has elucidated KCNMB2's tissue-specific roles, such as its contribution to vascular tone modulation or neuronal firing patterns, highlighting its potential as a therapeutic target or biomarker in diseases involving ion channel dysfunction.